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Abstract
Rhabdomyosarcoma (RMS) is the most common soft tissue
sarcoma that is found in children and has a poor outcome
for those with metastatic disease. Two histological groups
have been distinguished - embryonal (ERMS) and alveolar
(ARMS) forms. The ARMS subtype has higher rates of
metastasis, as well as higher levels of ELMO1, which is
thought to be involved in cell migration. Therefore, the
knock-down of ELMO1 by targeted siRNA could provide
a mechanism to prevent the metastatic behaviour of ARMS
cells. However, challenges still lie in the delivery of
nucleotides to a tumour site. Herein, we have described the
use of a variety of mesoporous silica nanoparticles as a
delivery system for siRNA that is specific for ELMO1 and
shown the effective reduction in cell invasive behaviour in
these cells.
Keywords Cancer, Metastasis, ELMO1, Nanoparticles,
siRNA
1. Introduction
Rhabdomyosarcoma (RMS) is the most common soft tissue
sarcoma in childhood and is thought to arise from cells of
the skeletal muscle lineage. In patients with localized
disease, the overall five-year survival rate has reached
approximately 80% due to the combined use of surgery,
radiation therapy and chemotherapy [1]. However, for
patients with metastatic disease, there have been few
improvements, with a five-year event free survival rate of
less than 30%.
RMS classically presents as two histological forms -
embryonal (ERMS) and alveolar (ARMS). Previous re‐
search from our group has shown that the more metastatic
ARMS subtype, which has a worse prognosis, also express‐
es higher levels of the protein ELMO1 [2]. ELMO1 is
thought to increase the invasive ability of cells and the
downregulation of ELMO1 in ARMS cells has been shown
to decrease the invasive nature of the cells. This indicates
that ELMO1 may be involved in the migration of ARMS
cells and subsequent metastasis. As such, it may be
considered as a novel target for the treatment of RMS. The
direct regulation of the expression of this protein could be
achieved through the use of siRNA molecules. These are
small double-stranded RNAs that mediate post-transcrip‐
tional gene silencing of a specific target protein by disrupt‐
ing messenger RNAs containing complementary
sequences. However, a major limitation of the use of siRNA
molecules both in vitro and in vivo is the inability of naked
siRNA to passively diffuse through cellular membranes.
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This is due to the strong anionic charge of the phosphate
backbone and consequent electrostatic repulsion from the
anionic cell membrane surface [3]. Furthermore, small
molecules are vulnerable to being destroyed by the
nucleases found in blood or other body fluids. This means
that there is a need to pack and protect the siRNA, but with
care that this does not affect the biological activity. Despite
this, the vast majority of in vivo studies using siRNA
technology have simply used high doses of nonmodified
naked siRNA [4-11]. This means that, to date, most siRNAs
in clinical trials are directly administered to local target
sites, such as the eye, the skin and the lung (administered
by inhalation), thereby avoiding the complexity of systemic
delivery. However, most tissues are not accessible and
direct injection may be difficult or impossible. Thus, there
is a need to develop safer and effective delivery systems.
One option for improved delivery is the utilization of
nanoparticles as carrier molecules.
Nanoparticles may be prepared from a wide range of
organic and inorganic materials. In this study, we have
chosen to use mesoporous silica nanoparticles (MSNPs).
This is due to the ability to easily control their structure and
morphology, and the potential for high surface areas and
pore volumes. The silica surface is also densely populated
with silanol groups, which can be modified with a wide
range of organic functional groups [12], allowing for the
modification with moieties such as siRNA. MSNPs have
also been shown to degrade over time in aqueous solution
[13], resulting in relatively harmless silicic acid. This may
be preferable to the use of non-metabolizable nanoparti‐
cles, such as carbon nanotubes or gold nanoparticles [14],
for long-term use. For the delivery of siRNA to tumours
and cells, the external diameter of the nanoparticles is an
important factor. Nanoparticles that have been adminis‐
tered systemically have been shown to accumulate in
tumours due to the enhanced permeation and retention
(EPR) effect [15]. Nanoparticles accumulate in tumours
because of the highly permeable blood vessels around
tumours. These have large fenestrations (greater than
100nm in size) as a result of rapid defective angiogenesis.
Tumours are also characterized by defective lymphatic
drainage, which results in the retention of the nanoparti‐
cles. At a cellular level, the uptake of nanoparticles is also
affected by size, as well as shape and charge. In general, it
appears that smaller nanoparticles enter and exit cells more
efficiently, as do spherical and positively charged nano‐
particles (for review, see [16]).
Therefore, in this study, we have investigated the utility of
mesoporous silica nanoparticles (MSNPs) as a delivery
system for ELMO1 siRNA in order to prevent the metastatic
spread of RMS.
2. Materials and Methods
2.1 Cell culture
The biological effect of the ELMO1 siRNA was tested in
vitro on the two paediatric Rhabdomyosarcoma cancer cell
lines RD (ATCC code CCL-136) and RH30 (ATCC code
CRL-7763), which were obtained from the Marican Type
Culture Collection (ATCC; Manassas; VA). The nanoparti‐
cles were also tested in Glioblastoma U87-MG cells (ATCC
code HTB-14) and breast cancer MCF7 cells (ATCC code
HTB-22). The cells were grown in growth medium (Dul‐
becco’s Modified Eagle’s Medium (DMEM); Aldrich)
supplemented with 10% foetal calf serum (Aldrich), 2 mM
L-Glutamine (Aldrich), 100 U/ml Penicillin (Aldrich) and
0.1 mg/ml Streptomycin (Aldrich). They were incubated at
37 0C in a 5% CO2 atmosphere. The cells were passaged
every three to four days.
2.2 Nanoparticle synthesis
Mesoporous silica nanoparticles were prepared according
to the method of Hom et al. [17] (Hexagonal-symmetry;
HMSNP), Nandiyanto et al. [18] (Blackberry-like; BMSNP),
Zhang et al. [19] (Chrysanthemum-like; CMSNP) and Moon
et al. [20] (Wrinkle-structure; WMSNP). Non-porous silica
nanoparticles (SNPs) were prepared according to the
method of Rao et al. [21]. We have previously fully charac‐
terized the particles and these details may be found in
Huang et al. [13].
2.3 Coating of particles with PEI
Polyethylenimine (PEI) was coated onto MSNPs before
transfection. In a typical PEI capping experiment, 10 mg
MSNPs or SNPs was suspended in 2 mL PEI solution (2.5
mg PEI/mL solution in water, Mw PEI = 24 kD). The
suspension was sonicated for 15 min in a water bath and
shaken for a further 30 min. The capped nanoparticles were
then collected by centrifugation at 8000rpm for 90 seconds
and washed with ddH2O thrice to remove any uncapped
polymer.
To check that the MSNPs were successfully coated with
positively charged PEI, the surface charge was determined
in physiological buffer (PBS, pH 7.4) before and after
coating. The surface charge of the MSNPs was determined
to be negative/ neutral prior to coating, and positive
following the capping procedure. This confirmed the
effectiveness of PEI capping.
The surface charge of MSNPs was measured using a
Zetasizer Nano ZS (Malvern, UK). To determine the
electrokinetic potential, or ζ potential (which represents the
surface charge of a colloidal suspension), the uncoated and
PEI coated MSNPs were suspended in PBS buffer (pH 7.4)
prior to the measurement. Thirty runs were read before the
calculation of zeta potential.
2.4 Cell viability assay
After the selected cell lines were treated with 0.05 mg/mL
PEI coated HMSNPs suspension for 24 hours, the cells were
washed twice with pre-warmed PBS. Then, 100 µL 0.5 mg/
mL MTT solution (0.5 mg/mL dissolved in a mixture of PBS:
growth medium, 1:9 v/v) was added to each well and
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incubated at 37 °C in darkness. After four hours incubation,
the supernatant was removed and the formazan, from the
reaction of MTT with viable cells, was solubilized with 100
µL DMSO per well. The absorbance was read at 570 nm
using a Tecan INFINITE 200 plate reader. The cell viability
was shown to have a linear correlation with absorbance.
2.5 siRNA loading efficiency on MSNPs
siRNA was re-suspended in 1x siRNA buffer (five times
diluted from 5x siRNA buffer [Dharmacon], comprising
300 mM KCl, 30 mM HEPES-pH 7.5, 1.0 mM MgCl2, with
RNase-free water), and aliquoted into a 20 µM siRNA stock
suspension. Immediately before any further experiment
(e.g., transfection), siRNA was loaded on PEI-MSNPs.
In a typical siRNA loading process, a 10 µL siRNA aliquot
(20 µM) and 10 µL of 6.25 mg/mL PEI-MSNP suspension
was mixed in 5 mL DMEM (no additives) and incubated at
RT for 30 min. FITC-conjugated siRNA (Santa Cruz
sc-36869) was used to measure the loading efficiency on the
siRNA-MSNP delivery system. After FITC-conjugated
siRNA loading, the siRNA-MSNP complex was washed
once with RNase-free water. Immediately after FITC-
conjugated siRNA was loaded, the fluorescence signal of
the siRNA-MSNP complex (Fc), loading supernatant (Fs)
and washed residue (Fr) was immediately determined after
the complex was washed, and every 24 hours up to 72
hours. All of the signals were read using a Tecan INFINITE










The efficacy of the transfection system was initially
investigated using a GFP expressing cell line. The U87-MG-
cGFP was a kind gift from Dr Karl Morten, NDOG, Oxford.
The siRNA transfection procedures were modified slightly
from the manufacturer’s instructions (Thermo Scientific™
and Santa Cruz Biotechnology™). U87-MG-cGFP cells
were plated at a density of 5 × 104 cells/well in antibiotic-
free media (DMEM supplemented with glutamine and
foetal bovine serum) at 37°C in a 5 % CO2 sterile humid
incubator and allowed to grow for 24 hours. The cells were
either incubated with: (i) buffer alone, (ii) siRNA with no
carrier, (iii) PEI-HMSNP, (iv) siRNA with DharmaFECT
transfection reagent [Dharmacon™] or (v) siRNA-MSNPs.
Immediately before transfection, the siRNA stock solution
(10 µM in RNase-free water) was diluted with 1X siRNA
buffer (Dharmacon™). For each well, either 2.5 µL siRNA
(or the equivalent amount of buffer in controls) was added
to 47.5 µL DMEM (serum-free). Separately, 1 µL Dharma‐
FECT (or the equivalent amount of buffer in controls) was
added to 49 µL DMEM (serum-free) in an RNase-free tube.
After a five-minute incubation, the two solutions were
mixed and incubated for 20 minutes. Subsequently, the
cells were washed once with PBS, and 400 µL antibiotic-free
media was added to each well before the transfection
mixture was added. Therefore, the final concentration of
siRNA was 25 nM per well. After a 24-hour transfection
period, the cells were washed with PBS twice and GFP
fluorescence was measured with a Tecan Infinite 200 plate
reader using a well scan mode (7x7 circle; filled) at Ex. 395/
Em. 510.
2.7 RT-PCR of ELMO1 knock-down
ELMO1 was knocked-down with either ELMO1-targetted
siRNA (ON-TARGETplus SMARTpool, human ELMO1,
Dharmacon, Thermo Scientific™; sense sequence: 5′-
GAAGTTATCAGTCGACATGCCGCCACCCGCG‐
GAC-3′ and antisense sequence: 5′-
ATGGTCTAGAAAGCTTTCACATATGAGGGCAGTCC
TTTC-3′), transfected with DharmaFECT transfection
reagent, ELMO1siRNA-HMSNP or ELMO1siRNA-
WMSNP, for 24 hours. A two-step RT-PCR method was
used in this study. The total RNA from each sample was
purified using ISOLATE II RNA Micro kit (Bioline™)
according to the manufacturer’s instructions. All of the
transfected RH30 or RD cells were washed with warm PBS,
trypsinized and collected in an RNase-free tube. Further‐
more, 100 µL Lysis Buffer RLY, 2 µL TCEP and 5 µL Carrier
RNA working solution (20 ng Carrier RNA) was added to
the collected cells separately and the lysate was vortexed
robustly twice after each addition. After the lysate was
filtered, 100 µL of a 70% ethanol solution was added. The
mixture was then placed onto an ISOLATE II RNA Micro
Column and centrifuged for 30 sec at 11,000 g. The RNA
bonded silica membrane in the column was then desalted
with Membrane desalting buffer before the DNase I
reaction mixture was added to digest the residue DNA on
the membrane. After 15 min DNA digestion at room
temperature, the column was washed with Wash Buffer
RW1 once and Wash Buffer RW2 twice. Finally, the total
RNA was eluted with 30 µL RNase-free water. The total
amount of RNA was measured with a NanoDrop 1000
(Thermo Scientific). cDNA was synthesized using a
SensiFAST cDNA Synthesis Kit according to the manufac‐
turer’s instructions. Briefly, 1 µg purified RNA was mixed
with 4 µL 5x TransAmp Buffer, 1 µL reverse transcriptase
and RNase free water to make up a 20 µL mixture. Thermal
cycling was performed: 25°C for 10 min (primer annealing);
42°C for 15 min (reverse transcription); 85°C for 5 min
(inactivation); 4°C hold. The second step of the RT-PCR was
then run with the SensiMix II Probe No-ROX kit (BIOL‐
INE™). The testing primer/probe was ELMO1 primer/
probe set with a FAM-MGB fluorescence tag (TaqMan;
assay ID Hs00404994_m1; Applied Biosystem) and a
control ACTB primer/probe set (TaqMan), assay ID
Hs01060665_g1, VIC-MGB (Applied Biosystem). Accord‐
ing to the supplier instructions, 2 µL template (cDNA
synthesized) was mixed with 10 µL 2x SensiMix™ II Probe
No-ROX, 1 µL ELMO1 TaqMan primer/probe, 1 µL ACTB
TaqMan primer/probe, and 6 µL DNase/RNase-free water.
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The samples were then placed in a Rotor-Gene 3000
(QIAGEN) thermal cycler; Cycle 1: 10 min at 95 °C for
polymerase activation, Cycle 2 to 46: 10 s at 95 °C then 60 s
at 60 °C (every cycle). All of the samples were tested in
triplicate.
The results obtained by qRT-PCR were quantified using the
comparative threshold method. Giulietti et al. [22] detailed
this method as ‘the amount of target, normalized to an
endogenous housekeeping gene and relative to the calibra‐
tor, is then given by 2-ΔΔCt, where ΔΔCt = ΔCtsample-
ΔCtcalibrator.’ Therefore, in this experiment, the housekeeping
gene was β-actin (ACTB), as the ‘calibrator’ in Giulietti’s
statement; ELMO1 was the ‘sample’ gene. The fold differ‐
ence of ELMO1 knockout = log (2-ΔΔCt), where ΔΔCt =
ΔCtELMO1- ΔCtACTB. Here, ΔCtELMO1 equals CtELMO1 of given
sample minus CtELMO1 of un-knockout sample (blank
control) on the same cell line on the same run batch; ΔCtACTB
equals CtACTB of given sample minus CtACTB of blank control.
All of the data were analysed with Rotor-Gene 6000 Series
Software 1.7 (QIAGEN) and Microsoft Excel 2010. The fold
difference of the ELMO1 expression against ACTB is
plotted.
2.8 Wound healing assay
In this study, a wound healing assay (scratch test) was
performed to evaluate cell migration and invasion. In a
typical test, RH30 or RD cells were cultured into a 24-well
sterile microplate (Corning). After 24 hours transfection
with ELMO1-targetted siRNA on different nanocarriers,
the transfected cells were allowed to proliferate, spread and
form a confluent monolayer. A 1000 µL pipette tip was used
as a pin tool to scratch across the cell layer and remove the
scratched content, hence form a cell-free zone in each well.
Images were collected pre- and post- migration. The
average width (measured twice across both the vertical and
the horizontal scratches) and cell mobility were calculated
as:
 






3. Results and Discussion
The ability to effectively silence the genes that are involved
in metastasis has wide therapeutic potential in the fight
against cancer. However, to clinically achieve this, it is
necessary for siRNA to be effectively delivered to the
tumour site. Unmodified siRNA is unstable in the blood‐
stream, can be immunogenic and does not readily cross cell
membranes [23]. It is vital that the siRNA is delivered to the
interior of the target cells in order to be incorporated into
the RNAi machinery. However, siRNA molecules are too
large and too hydrophilic to cross the cell membrane.
Therefore, they require chemical modification or a carrier
material to enter the cells. Herein, we explore the use of a
silica nanoparticle delivery system. We have previously
characterized a number of different MSNPs [13] and their
hydrodynamic diameter and surface area are summarized
in Table 1. The particles are named in accordance with their
physical appearance; Blackberry-like (BMSNP), Chrysan‐
themum-like (CMSNP), Hexagonal-symmetry (HMSNP),
Wrinkle-structure (WMSNP), and solid (SNP; i.e., not
porous). The particles increase in diameter in the order:
BMSNP< HMSNP<WMSNP< CMSNP. The CMSNPs are
most likely too large for systemic administration but may
be used for direct intratumoural injection. Meanwhile, the
other particles would be an appropriate size to take
advantage of the EPR effect. The different morphology
particles also show differences in the surface areas such that
BMSNP< WMSNP< CMNSP< HMSNP. TEM images of the
particles are shown (Figure 1) and it can be seen that the
overall shape of all the MSNPs is roughly spherical, which
is known to be the preferred shape for cellular uptake.
Thus, the shape and exceptionally large surface area of
mesoporous particles makes them particularly suitable as
carriers for siRNA.
In order to attract the siRNA to the surface of the silica
particles, a PEI coating was applied. PEI is a cationic
polymer and attracts the negatively charged siRNA so that
it is bound by electrostatic interaction to the surface of the
particle. The PEI coating on the nanoparticles was too thin
to be assessed by TEM (data not shown) but the change in
zeta potential (Table 1) clearly indicates the presence of the
positively charged polymer on the surface.
Uncomplexed PEI could potentially be harmful to cells and
a number of studies have reported toxicity [24]. Therefore,
we assessed the extreme situation, where no nucleotide was
bound to the PEI coated nanoparticles. To test this, PEI
coated HMSNPs were incubated with a variety of different
cell lines. Figure 2 shows that there was a 20% (± 7%)
Figure 1. TEM images of MSNPs. Representative images are shown of: (A) Solid nanoparticles (SNPs; 50nm scale bar), (B) Hexagonal mesoporous silica
nanoparticles (HMSNP; 50nm scale bar), (C) Blackberry-like mesoporous silica nanoparticles (BMSNP; 20nm scale bar), (D) Chrysanthemum-like silica
nanoparticles (CMSNP; 200nm scale bar) and (E) Wrinkle-structured mesoporous silica nanoparticle (WMSNP; 100nm scale bar).
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decrease in the cell viability in RH30 cells, although this was
statistically insignificant. The cell viability was further
decreased in the other cell lines tested by up to 27% (± 6%)
in MCF7 cells. However, it is unlikely that all of the sites
would be unbound. Therefore, the effects of the PEI would
be mitigated (see also Figure 6).
Figure 2. Viability of RH30, RD, U87-MG and MCF7 cells after treatment
with PEI coated HMSNP. The cells were treated with the same concentration
used in transfection; the viability was assessed with MTT assay. Data are
presented as mean± SD of triplicate samples. (n.s. =not significant p>0.02, *p
≤ 0.05, **p ≤ 0.01,***p ≤ 0.005).
To assess the loading of siRNA onto the different MSNPs,
FITC-labelled siRNA was incubated with the PEI coated
particles. The amount of siRNA bound to each type of
particle was then assessed by measuring the fluorescence
signal. The data shown in Figure 3 illustrate the variability
in the amount of siRNA bound by each of the different
morphology MSNPs. These data were used in the subse‐
quent experiment to normalize the amounts of siRNA
introduced. Hence, the amount of nanoparticles incubated
with cells was varied accordingly.
An initial test was devised to assess the ability of the five
different MSNPs to deliver siRNA to cells in comparison to
DharmaFECT, a standard lipid based transfection agent.
The particles were assessed in their ability to introduce
GFP-siRNA into GFP expressing U87-MG cells and to
reduce the fluorescence signal from the cells. Since the
siRNA loading efficiency of the different particle morphol‐
ogies varied (Figure 3), the number of nanoparticles was
normalized so that each cell sample would be incubated
with the same amount of siRNA. Of the morphologies
tested, BMSNPs, CMSNPs and SNPs were shown to have
equal efficacy to DharmaFECT, within error (Figure 4).
However, compared to DharmaFECT, the delivery of
siRNA with HMSNPs and WMSNPs demonstrated a much
greater reduction in GFP fluorescence as a result of the gene
knockdown; up to 23 ± 4 % for HMSNPs (p < 0.01), and 21
± 4 % for WMSNPs (p < 0.01). The low rate of knock-down
that is seen with CMSNPs may be due to their size - they
are the largest of the particles tested, with a diameter of
754nm (Table 1). The uptake of nanoparticles has been
shown to be strongly size-dependent and uptake processes
are affected by the bending and stretching forces of the
membrane that is involved in endocytosis [25]. BMSNPs
have been previously shown to have a positive zeta
potential [13]. Since uptake is known to be affected by
electrostatic forces [25], this may explain the lower efficacy
of these particles in delivering siRNA to the cells. The SNPs
are likely to have a much higher ratio of nanoparticles to
siRNA. This is because the surface area is much lower due
to the lack of porosity. A greater number of nanoparticles
may adversely affect the viability of the cell and, subse‐
quently, the siRNA machinery. The HMSNPs and
WMSNPs are both a suitable size for cell uptake and have
a high surface area for loading of siRNA.
A number of studies have shown hypothesized mecha‐
nisms for the cellular uptake of MSNPs, indicating how
different nanoparticles may be endocytosed and trafficked
Figure 3. siRNA loading of MSNPS. The different particle morphologies
were coated with PEI and incubated with FITC labelled siRNA. The
fluorescence signal from the bound siRNA was used to calculate the loading





Zeta potential before coating Zeta potential after coating
HMSNP 98.77 ±1.32 1110.89 ±1.73 -31.43 ±0.61 25.73 ±0.64
BMSNP 57.47 ±1.9 303.02 ±1.00 1.13 ±0.35 18.33 ±0.25
CMSNP 998.81 ±3.2 934.18 ±1.03 -18.00 ±0.62 20.4 ±0.46
WMSNP 234.53 ±1.08 511.56 ±1.99 -59.27 ±2.22 21.55 ±0.23
Table 1. Summary of MSNP measurements. Hydrodynamic diameter (nm) was assessed using a CPS disc centrifuge and the polydispersity index is indicated.
The surface area (m2/g) was determined by BET. The zeta potential (mV) of the nanoparticles was assessed before and after coating with PEI (mean ± standard
deviation, n=3).
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in cancer cell lines [25-30]. However, the proposed mecha‐
nisms of MSNPs endocytosis would be affected by the cell
type, size, surface charge, surface hydrophobicity and
shape of MSNPs [28]. A small number of investigations
have attempted to track MSNPs in cells. For instance, Sun
et al. [26] monitored the speed, shape and vertical positions
of un-functionalised HMSNPs in live A549 cells using
differential interference contrast microscopy. Other
investigations on MSNPs endocytosis have been undertak‐
en using TEM (including cryo-TEM) [27-30] and confocal
fluorescence microscopy [28, 30]. However, the mecha‐
nisms of nanoparticle uptake have not yet been fully
elucidated.
Thus, the efficacy of the delivery of the siRNA to the cell
machinery is likely to be a function of the efficiency of the
uptake of the nanoparticles into the cells. However, this
may also vary depending upon the specific cell line.
Figure 4. Knock-down of GFP in U87-MG-cGFP cells. The cells were
transfected with either DharmaFECT reagent, MSNPs or SNPs. The siRNA
was targeted against GFP and a total of 25ng of siRNA was used for
transfection. GFP fluorescence was measured and shown as the % reduction
compared to the corresponding control. Data are presented as mean ± SD of
triplicate samples.
Subsequently, the nanoparticles were applied to our
system of interest. The nanoparticles were tested against
the paediatric Rhabdomyosarcoma lines, RD (ERMS) and
RH30 (ARMS), and coated with siRNA coding for ELMO1.
Previous studies have shown that the exogenous expres‐
sion of ELMO1 in the less metastatic line RD, and in
myoblasts which have low/ no endogenous ELMO1
expression, increased their invasive nature such that all of
the transfected cells were able to migrate [2]. Our studies
confirmed that there was a 0.51 fold ± 0.28 (SD) increase in
the levels of ELMO1 in RH30 compared to RD (data not
shown). Therefore, we first assessed the loaded nanoparti‐
cles by use of a wound healing assay. This is a simple
method that can be used to mimic the migration of cells in
vivo [31]. Thus, the assay was used to determine the
metastatic potential of RD and RH30 cells after siRNA
treatment using the different delivery methods (Figure 5
and S1). The control, untreated RH30 and RD cells showed
85.7% (± 14.0 %) and 79.6% (± 1.2 %) closure of the gap over
the duration of the assay, respectively. Bare ELMO1 siRNA
was added to the cells and showed no significant difference
in gap closure to the controls for either cell type. This may
be either due to the breakdown of the unprotected siRNA
in the cell culture medium or the inability of the siRNA to
penetrate the cell membrane and access the cellular
material. As a further control, non-targeting (NT) siRNA
was introduced into the cells using the DharmaFECT
reagent. This also showed no significant increase in gap
closure over the control, with 83.5% (± 10.1 %) and 83.8% (±
1.0 %) gap closure for the RH30 and RD cells, respectively.
In the presence of ELMO1 targeted siRNA, in the RH30
cells, all of the MSNP delivery systems were as effective as
the DharmaFECT reagent (no significant difference,
student t-test shows p> 0.1 in all cases). A similar case was
seen for the RD cells (no significant difference, student t-
test shows p> 0.2 in all cases), with the exception of the non-
porous (SNP) particles. This is a promising outcome, since
a reagent, such as DharmaFECT, could not be used for in
vivo delivery of siRNA. However, an equivalent efficacy
illustrates that MSNPs have the potential to be an effective
delivery system.
To further assess the MSNPs as delivery systems, the gene
expression levels were determined. Since HMSNPs and
WMSNPs were shown to carry the most siRNA (Figure 3),
they were used in the knock-down experiment. The gene
expression levels in the control groups, where either no
siRNA (cells only, or nanoparticles only) or non-targeting
siRNA was administered (NT@MSNP), showed very little
fold-change (Figure 6). However, for both the RD and RH30
cell types, there was a statistically significant increase in the
gene knock-down when the targeted siRNA was delivered
by the nanoparticle carrier (ELMO1@MSNP) compared to
lipid transfection with DharmaFECT (p ≤ 0.005). The cells
that were incubated with the MSNPs showed approximate‐
ly double the fold-difference reduction in gene expression
that was seen with the lipid transfection reagent. While the
knock-down of ELMO1 gene expression after delivery of
the targeted siRNA by the MSNPs was almost double that
of the DharmaFECT (Figure 6), the MSNP delivery was
equally effective as DharmaFECT in the invasion test
(Figure 5). This may be due to the fact that the qPCR results
do not necessarily correlate with protein levels, and peak
levels in repression of mRNA and protein may differ.
There is evidence to suggest that the inhibition of a single
step in a metastatic cascade can lead to the suppression of
metastasis [21-23]. An integral part of metastasis involves
cell migration and this is required at virtually every step of
the metastatic cascade. Therefore, ELMO1 may be consid‐
ered as a candidate for the reduction of metastatic potential,
particularly in the ARMS subtype of RMS. Furthermore,
MSNPs have been shown to be suitable nanocarriers for
siRNA, and that the architecture of the particles affects both
the loading with nucleotide and the efficacy of transfection.
It would be interesting to further investigate the mecha‐
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nism of endocytosis for the different nanoparticles, al‐
though this is beyond the scope of the present study.
There are a very limited number of siRNA delivery systems
that are currently in clinical trials, and none have yet been
approved by the FDA. For this to happen, two major
bottlenecks must be overcome: the abrogation of off-target
silencing effects and efficient delivery of siRNA [32]. We
have shown here that nanocarriers, such as MSNPs, have
the potential to significantly contribute to the latter.
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fold-difference, as determined by qRT-PCR, is shown. Data are presented as the mean ± SD of triplicate samples. Significance was tested using a two tailed t-
test compared to the cells treated with ELMO1@DharmaFECT for each cell line (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.005).
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Appendix
Figure S1 Scratch test showing cell invasion under different test conditions. RH30 cells were transfected with ELMO1 or a non-targeted siRNA for 72 hours.
Subsequently, the confluent cell layer was scratched with a pipette tip and the images were recorded at (i) t=0 and (ii) t= 24 hours. Representative images are
shown for: (A) Untreated control cells, (B) Bare ELMO1-targeted siRNA, (C) non-targeted siRNA and DharmaFECT, (D) ELMO1 siRNA and DharmaFECT,
(E) ELMO1 and SNP, (F) ELMO1 and HMSNP, (G) ELMO1 and BMSNP, (H) ELMO1 and CMSNP and (I) ELMO1 and WMNSP. The arrows indicate cell free
gap. Scale bar = 200 µm.
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